INTANGIBLE ASSETS (Details Narrative) - USD ($) |
1 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|
Oct. 12, 2018 |
Dec. 31, 2025 |
Dec. 31, 2024 |
Mar. 04, 2025 |
|
| Accumulated amortization | $ (36,440) | $ (7,352) | ||
| Business combination, intangible assets acquired | 249,500 | |||
| Naltrexone Implant Formulation [Member] | Australia from Trinity Compound Solutions [Member] | ||||
| Patent acquired | $ 15,200 | |||
| Estimated useful lives | 13 years | |||
| Trademarks [Member] | ||||
| Business combination, intangible assets acquired | 249,500 | $ 249,500 | ||
| Customer Base [Member] | ||||
| Accumulated amortization | 27,910 | |||
| Amortization expense | $ 27,910 | |||
| Estimated useful lives | 13 years | 10 years | ||
| Business combination, intangible assets acquired | $ 336,200 | |||
| Patents [Member] | ||||
| Amortization expense | $ 1,178 | $ 1,179 | ||
| Accumulated amortization | $ 8,530 | |||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of identifiable finite-lived intangible asset acquired in business combination and recognized at acquisition date. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Accumulated amortization on long-term land leases capitalized as part of real property. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|